

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Patent of: Saksena, et al.

Docket No.: IN01159K1-US

Patent No.: 7,244,721

Serial No.: 10/052,386

Issued: July 17, 2007

For: PEPTIDES AS NS3-SERINE PROTEASE  
INHIBITORS OF HEPATITIS C VIRUS

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

STATEMENT UNDER 37 CFR 3.73(b)

Sir:

Schering Corporation, a corporation and Dendreon Corporation, a corporation, state together they are the assignees of the entire right, title and interest in the patent identified above by virtue of a chain of title from the inventors to the current assignees as follows:

Dendreon Corporation

1. From: Scott Jeffrey Kemp, et al. (4 of the 28 inventors) To: Corvas International, Inc.  
The document was recorded in the United States Patent and Trademark Office at Reel 017284,  
Frame 0630.

2. From: Corvas International, Inc. To: Dendreon San Diego LLC. The document was  
recorded in the United States Patent and Trademark Office at Reel 017287, Frame 0168.

3. From: Dendreon San Diego LLC To: Dendreon Corporation. The document was  
recorded in the United States Patent and Trademark Office at Reel 017305, Frame 0055.

Dendreon Corporation

The undersigned, whose title is supplied below, is authorized to act on behalf of Dendreon Corporation.

By   
Kevin Helmbacher  
Chief Patent Counsel


Date: 5/16/11

Schering Corporation

1. From: Anil Saksena, et al. (24 of the 28 inventors) To: Schering Corporation. The document was recorded in the United States Patent and Trademark Office at Reel 017284, Frame 0700.

Schering Corporation:

The undersigned, whose title is supplied below, is authorized by Merck & Co., Inc. to act on behalf of Schering Corporation pursuant to the attached General Corporate Resolution No. 5, dated February 22, 2011. Schering Corporation is a subsidiary of Merck & Co., Inc. Attached is a copy of Exhibit 21 from the Merck & Co., Inc. 10K Annual Report, filed February 21, 2011, listing different Merck & Co., Inc. subsidiaries, including Schering Corporation. The copy of Exhibit 21 was obtained from Merck & Co., Inc.'s on-line SEC filing.

By   
Sheldon O. Heber  
Managing Counsel - Patents

Date: 6-6-2011